Mace L. Rothenberg

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

Matrix Metalloproteinases: Biologic Activity and Clinical Implications

Amy R. Nelson, Barbara Fingleton, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2000 · 1.6K citations

Medicine, Cancer Biology, Oncology +14

Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

Mace L. Rothenberg, Amit M. Oza, Robert Bigelow et al. · Journal of Clinical Oncology · 2003 · 645 citations

Medicine, Oncology, Pharmacology +17

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2002 · 578 citations

Medicine, Oncology, Pharmacology +17

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

Mace L. Rothenberg, Malcolm J. Moore, M. Christine Cripps et al. · Annals of Oncology · 1996 · 569 citations · Full text

Medicine, Oncology, Pharmacology +9